Vutrisiran Dosage
Medically reviewed by Drugs.com. Last updated on Feb 13, 2025.
Applies to the following strengths: 25 mg/0.5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis
Recommended dose: 25 mg administered by subcutaneous injection once every 3 months
Uses: Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) and cardiomyopathy of wild-type or hATTR in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits in adults.
Renal Dose Adjustments
Mild and Moderate Renal Dysfunction: No adjustment recommended.
Severe Renal Dysfunction and End-Stage Renal Disease: Data not available
Liver Dose Adjustments
Mild Liver Dysfunction: No adjustment recommended.
Moderate and Severe Liver Dysfunction: Data not available
Precautions
CONTRAINDICATIONS: None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- This drug is for subcutaneous administration only.
- Should be administered by a healthcare professional.
- If a dose is missed, administer as soon as possible and resume dosing every 3 months from the most recently administered dose.
- Consult the manufacturer product information for further preparation and administration instructions.
- Vitamin A supplementation is recommended.
Storage requirements:
- Store at 2C to 30C (36F to 86F) in the original carton until ready for use.
- Do not freeze.
General: To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring:
- Metabolic: Vitamin A serum levels prior and during treatment
Patient advice:
- Read the Patient Information and Instructions for Use.
- Female patients should inform their healthcare provider if they are pregnant or planning to become pregnant while taking this drug.
- Patients should contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency such as night blindness.
More about vutrisiran
- Compare alternatives
- Reviews (1)
- Side effects
- During pregnancy
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Patisiran
Patisiran (brand name Onpattro) is an injectable treatment for polyneuropathy caused by hereditary ...
Acoramidis
Acoramidis systemic is used for cardiomyopathy of transthyretin-mediated amyloidosis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.